Advertisement

European Child & Adolescent Psychiatry

, Volume 28, Issue 10, pp 1395–1405 | Cite as

Differences in the regulation of inflammatory pathways in adolescent- and adult-onset first-episode psychosis

  • C. MorenoEmail author
  • M. Parellada
  • K. S. MacDowell
  • B. García-Bueno
  • B. Cabrera
  • A. González-Pinto
  • P. Saiz
  • A. Lobo
  • R. Rodriguez-Jimenez
  • E. Berrocoso
  • M. Bernardo
  • J. C. Leza
  • From the FLAMM-PEPs study, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
Original Contribution

Abstract

A precise description of the inflammatory response in first-episode psychosis (FEP) by age of onset does not exist. We explored baseline and 6-month follow-up differences in the pro/anti-inflammatory balance in plasma and peripheral blood mononuclear cells in adolescent-onset FEP (≤ 18 y.o., N = 27) and adult-onset FEP (≥ 25 y.o., N = 43) using non-parametric 1-category ANCOVA, with age group as an independent variable and values of pro- and anti-inflammatory markers at baseline and at follow-up as dependent variables. We used a non-parametric repeated-measures mixed-effects model to explore the baseline/6-month change in pro- and anti-inflammatory markers within adolescent- and adult-onset groups, exploring differential trajectories of change by means of the interaction of time by age-of-onset group. Levels of the nuclear transcription factor (NFκB), a master regulator of the inflammatory and oxido/nitrosative status of cells, were higher in adolescent-onset FEP both at baseline and after 6 months. During follow-up, we found further increases in levels of soluble inflammatory markers (PGE2 and NO2) only in adolescent-onset FEP. In contrast, in adult-onset FEP, the expression of inducible NO synthase (iNOS), which is also pro-inflammatory, tended to decrease, with no further increase in other pro-inflammatory markers. Significant differences in the direction of change by age-of-onset cohort exist only for NFκB (F = 4.165, df = 2, 70.95, p = 0.019). Our results support the existence of changes in the pro/anti-inflammatory balance in FEP depending on the neurodevelopmental stage at illness onset. These results also suggest that inflammation may be a potential therapeutic target in adolescent-onset FEP.

Keywords

Inflammation Psychosis Early-onset psychosis Inflammatory pathways 

Notes

Acknowledgements

Supported by CIBERSAM Intramural Projects 2010 (P02): Flamm-PEPs, Inflammatory alterations in schizophrenia: search of biological markers in first-psychotic episodes; the Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III (PI08/0208, PI 11/00325, PI12/01303, PI14/02069, PI17/02227); co-financed by ERDF Funds from the European Commission, “A way of making Europe”, CIBERSAM; Madrid Regional Government (B2017/BMD-3740 AGES-CM-2), European Union Structural Funds and European Union Seventh Framework Program under grant agreements FP7-HEALTH-2009-2.2.1-2-241909 (Project EU-GEI), FP7-HEALTH-2009-2.2.1-3-242114 (Project OPTiMISE), FP7-HEALTH-2013-2.2.1-2-603196 (Project PSYSCAN) and FP7- HEALTH-2013-2.2.1-2-602478 (Project METSY); the Government of Catalonia, Secretaria d’Universitats i Recerca del Departament d’Economia i Coneixement (2014SGR441); Fundación Alicia Koplowitz, Fundación Familia Alonso, and Fundación Mutua Madrileña. This work was developed (in part) at the Centro Esther Koplowitz (Barcelona).

Conflict of interest

C Moreno reports grants from European Union Funds, Instituto de Salud Carlos III Spanish Ministry of Economy and Competitiveness, and consultancy for Janssen, Servier, Nuvelution, Otsuka and Lundbeck unrelated to the submitted work; M Parellada reports grants from Spanish Ministry of Economy and Competitiveness, Instituto de Salud Carlos III, during the conduct of the study; grants from CIBERSAM, grants from Fundación Alicia Koplowitz, Horizon 2020 and consultancy for Servier, unrelated to the submitted work; A Gonzalez-Pinto has received grants and served as consultant, advisor or CME speaker for the following entities: AstraZeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly, Janssen-Cilag, Lundbeck, Merck, Otsuka, Pfizer, Sanofi-Aventis, Servier, the Spanish Ministry of Science and Innovation (CIBERSAM), the Ministry of Science (Carlos III Institute), the Basque Governement, the Stanley Medical Research Institute, and Wyeth.; P Saiz has been a consultant to or has received honoraria or grants from Adamed, AstraZeneca, Brainpharma, Bristol-Myers Squibb, CIBERSAM, Esteve, European Comission, Ferrer inCode, GlaxoSmithKline, Instituto de Salud Carlos III, Janssen-Cilag, Lilly, Lundbeck, Otsuka, Pfizer, Plan Nacional Sobre Drogas, Rovi and Servier.; A Lobo reports personal fees from Lundbeck, personal fees from Lilly, unrelated to the submitted work; R Rodriguez-Jimenez has been a consultant for, spoken at activities of, or received  grants from: Instituto de Salud Carlos III, Fondo de Investigación Sanitaria (FIS), Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), Madrid Regional Government (S2010/ BMD-2422 AGES), Janssen Cilag, Lundbeck, Otsuka, Pfizer, Ferrer, Juste; M Bernardo has been a consultant for, received grant/research support and honoraria from, and been on the speakers/advisory board of ABBiotics, Adamed, Almirall, AMGEN, Boehringer, Eli Lilly, Ferrer, Forum Pharmaceuticals, Gedeon, Hersill, Janssen-Cilag, Lundbeck, Otsuka, Pfizer, Roche, Servier and has obtained research funding from the Spanish Ministry of Health, the Spanish Ministry of Science and Education, the Spanish Ministry of Economy and Competiveness, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM), by the Government of Catalonia, Secretaria d'Universitats i Recerca del Departament d'Economia i Coneixement, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), and the 7th Framework Program of the European Union. The remaining authors have nothing to disclose apart from grants from National or Regional public scientific agencies.

References

  1. 1.
    Alonso J, Saha S, Lim CCW, Aguilar-Gaxiola S, Al-Hamzawi A, Benjet C, Bromet EJ, Degenhardt L, de Girolamo G, Esan O, Florescu S, Gureje O, Haro JM, Hu C, Karam EG, Karam G, Kovess-Masfety V, Lepine JP, Lee S, Mneimneh Z, Navarro-Mateu F, Posada-Villa J, Sampson NA, Scott KM, Stagnaro JC, Ten Have M, Viana MC, Kessler RC, McGrath JJ, WHO World Mental Health Survey Collaborators (2018) The association between psychotic experiences and health-related quality of life: a cross-national analysis based on World Mental Health Surveys. Schizophr Res May 16. pii: S0920-9964(18)30254-8. doi: 10.1016/j.schres.2018.04.044. [Epub ahead of print].PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Lee FS, Heimer H, Giedd JN, Lein ES, Šestan N, Weinberger DR, Casey BJ (2014) Adolescent mental health-opportunity and obligation. Science 346(6209):547–549PubMedPubMedCentralCrossRefGoogle Scholar
  3. 3.
    Veru F, Jordan G, Joober R, Malla A, Iyer S (2016) Adolescent vs. adult onset of a first episode psychosis: impact on remission of positive and negative symptoms. Schizophr Res 174(13): 183-8.PubMedCrossRefGoogle Scholar
  4. 4.
    Kao and Liu (2010) Effects of age of onset on clinical characteristics in schizophrenia spectrum disorders. BMC Psychiatry 10:63.  https://doi.org/10.1186/1471-244X-10-63 CrossRefGoogle Scholar
  5. 5.
    Ballageer T, Malla A, Manchanda R, Takhar J, Haricharan R (2005) Is adolescent-onset first-episode psychosis different from adult onset? J Am Acad Child Adolesc Psychiatry 44(8):782–789PubMedCrossRefGoogle Scholar
  6. 6.
    Hui CL, Li AW, Leung CM, Chang WC, Chan SK, Lee EH, Chen EY (2014) Comparing illness presentation, treatment and functioning between patients with adolescent- and adult-onset psychosis. Psychiatry Res 220(3):797–802.  https://doi.org/10.1016/j.psychres.2014.08.046 PubMedCrossRefGoogle Scholar
  7. 7.
    Stentebjerg-Olesen M, Pagsberg AK, Fink-Jensen A, Correll CU, Jeppesen P (2016) Clinical characteristics and predictors of outcome of schizophrenia-spectrum psychosis in children and adolescents: a systematic review. J Child Adolesc Psychopharmacol 26(5):410–427.  https://doi.org/10.1089/cap.2015.0097 PubMedCrossRefGoogle Scholar
  8. 8.
    Langeveld J, Joa I, Friis S, ten Velden Hegelstad W, Melle I, Johannessen JO, Opjordsmoen S, Simonsen E, Vaglum P, Auestad B, McGlashan T, Larsen TK (2012) A comparison of adolescent- and adult-onset first-episode, non-affective psychosis: 2-year follow-up. Eur Arch Psychiatry Clin Neurosci 262(7):599–605.  https://doi.org/10.1007/s00406-012-0308-9 PubMedCrossRefGoogle Scholar
  9. 9.
    Schimmelmann BG, Conus P, Cotton S, McGorry PD, Lambert M (2007) Pre-treatment, baseline, and outcome differences between early-onset and adult-onset psychosis in an epidemiological cohort of 636 first-episode patients. Schizophr Res 95(1–3):1–8PubMedCrossRefGoogle Scholar
  10. 10.
    Nicolson R, Brookner FB, Lenane M, Gochman P, Ingraham LJ, Egan MF, Kendler KS, Pickar D, Weinberger DR, Rapoport JL (2003) Parental schizophrenia spectrum disorders in childhood-onset and adult-onset schizophrenia. Am J Psychiatry 160(3):490–495PubMedCrossRefGoogle Scholar
  11. 11.
    Fatjó-Vilas M, Papiol S, Estrada G, Bombín I, Peralta V, Rosa A, Parellada M, Miret S, Martín M, Lázaro L, Campanera S, Muñoz MJ, Lera-Miguel S, Arias B, Navarro ME, Castro-Fornieles J, Cuesta MJ, Arango C, Fañanás L (2011) Dysbindin-1 gene contributes differentially to early- and adult-onset forms of functional psychosis. Am J Med Genet B Neuropsychiatr Genet 156B(3):322–333.  https://doi.org/10.1002/ajmg.b.31166 PubMedCrossRefGoogle Scholar
  12. 12.
    Pina-Camacho L, Del Rey-Mejías A, Janssen J, Bioque M, González-Pinto A, Arango C, Lobo A, Sarró S, Desco M, Sanjuan J, Lacalle-Aurioles M, Cuesta MJ, Saiz-Ruiz J, Bernardo M, Parellada M, PEPs Group (2016) Age at first episode modulates diagnosis-related structural brain abnormalities in psychosis. Schizophr Bull 42(2):344–357.  https://doi.org/10.1093/schbul/sbv128 CrossRefGoogle Scholar
  13. 13.
    Mondelli V, Ciufolini S, Belvederi Murri M, Bonaccorso S, Di Forti M, Giordano A, Marques TR, Zunszain PA, Morgan C, Murray RM, Pariante CM, Dazzan P (2015) Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophr Bull 41(5):1162–1170PubMedPubMedCentralCrossRefGoogle Scholar
  14. 14.
    García-Bueno B, Bioque M, Mac-Dowell KS, Barcones MF, Martínez-Cengotitabengoa M, Pina-Camacho L, Rodríguez-Jiménez R, Sáiz PA, Castro C, Lafuente A, Santabárbara J, González-Pinto A, Parellada M, Rubio G, García-Portilla MP, Micó JA, Bernardo M, Leza JC (2014) Pro-/anti-inflammatory dysregulation in patients with first episode of psychosis: toward an integrative inflammatory hypothesis of schizophrenia. Schizophr Bull 40(2):376–387PubMedCrossRefGoogle Scholar
  15. 15.
    Stolp H (2013) Neuropoietic cytokines in normal brain development and neurodevelopmental disorders. Mol Cell Neurosci 53:63–68PubMedCrossRefGoogle Scholar
  16. 16.
    Aguilar-Valles A, Jung S, Poole S, Flores C, Luheshi GN (2012) Leptin and interleukin-6 alter the function of mesolimbic dopamine neurons in a rodent model of prenatal inflammation. Psychoneuroendocrinology 37(7):956–996PubMedCrossRefGoogle Scholar
  17. 17.
    Williams M, Zhang Z, Nance E, Drewes JL, Lesniak WG, Singh S, Chugani DC, Rangaramanujam K, Graham DR, Kannan S (2017) Maternal inflammation results in altered tryptophan metabolism in rabbit placenta and fetal brain. Dev Neurosci. 39(5):399–412.  https://doi.org/10.1159/000471509 PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    García-Bueno B, Bioque M, MacDowell KS, Santabárbara J, Martínez-Cengotitabengoa M, Moreno C, Sáiz PA, Berrocoso E, Gassó P, Fe Barcones M, González-Pinto A, Parellada M, Bobes J, Micó JA, Bernardo M, Leza JC (2014) Pro-/antiinflammatory dysregulation in early psychosis: results from a 1-year follow-up study. Int J Neuropsychopharmacol 18(2):1–10Google Scholar
  19. 19.
    Fraguas D, Díaz-Caneja CM, Rodríguez-Quiroga A, Arango C (2017) Oxidative stress and inflammation in early onset first episode psychosis: a systematic review and meta-analysis. Int J Neuropsychopharmacol 20(6):435–444.  https://doi.org/10.1093/ijnp/pyx015 PubMedPubMedCentralCrossRefGoogle Scholar
  20. 20.
    Hollingshead AB, Redlich FC (1958) Social class and mental illness. Wiley, New YorkCrossRefGoogle Scholar
  21. 21.
    Shaw P, Kabani NJ, Lerch JP, Eckstrand K, Lenroot R, Gogtay N, Greenstein D, Clasen L, Evans A, Rapoport JL, Giedd JN, Wise SP (2008) Neurodevelopmental trajectories of the human cerebral cortex. J Neurosci 28(14):3586–3594PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Lebel C, Beaulieu C (2011) Longitudinal development of human brain wiring continues from childhood into adulthood. J Neurosci 31(30):10937–10947PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Bernardo M, Bioque M, Parellada M, Saiz-Ruiz J, Cuesta MJ, Llerena A, Sanjuán Castro-Fornieles J, Arangoa C, Cabrera B, PEPs GROUP (2013) Assessing clinical and functional outcomes in a gene–environment interaction study in first episode of psychosis (PEPs). Revista de Psiquiatría y Salud Mental (English Edition) 6(1):4–16.  https://doi.org/10.1016/j.rpsmen.2012.11.001 CrossRefGoogle Scholar
  24. 24.
    First M (1999) Entrevista clínica estructurada para los trastornos del eje-I del DSM-IV. Masson, BarcelonaGoogle Scholar
  25. 25.
    Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, Williamson D, Ryan N (1997) Schedule for affective disorders and schizophrenia for school-age children-present and lifetime version (K-SADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36(7):980–988PubMedCrossRefGoogle Scholar
  26. 26.
    Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261–276PubMedCrossRefGoogle Scholar
  27. 27.
    Young RC, Biggs JT, Ziegler VE, Meyer DA (1978) A rating scale for mania: reliability, validity and sensitivity. Br J Psychiatry 133:429–435PubMedCrossRefGoogle Scholar
  28. 28.
    Montgomery SA, Asberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 134:382–389PubMedCrossRefGoogle Scholar
  29. 29.
    Shaffer D, Gould MS, Brasic J, Ambrosini P, Fisher P, Bird H, Aluwahlia S (1983) A children's global assessment scale (CGAS). Arch Gen Psychiatry 40(11):1228–1231PubMedCrossRefGoogle Scholar
  30. 30.
    Endicott J, Spitzer RL, Fleiss JL, Cohen J (1976) The global assessment scale. A procedure for measuring overall severity of psychiatric disturbance. Arch Gen Psychiatry 33(6):766–771PubMedCrossRefGoogle Scholar
  31. 31.
    Gardner DM, Murphy AL, O'Donnell H, Centorrino F, Baldessarini RJ (2010) International consensus study of antipsychotic dosing. Am J Psychiatry 167(6):686–693PubMedCrossRefGoogle Scholar
  32. 32.
    Perkins DO, Leserman J, Jarskog LF, Graham K, Kazmer J, Lieberman JA (2000) Characterizing and dating the onset of symptoms in psychotic illness: the Symptom Onset in Schizophrenia (SOS) inventory. Schizophr Res 44(1):1–10PubMedCrossRefGoogle Scholar
  33. 33.
    Conover WJ, Iman RL (1981) Rank transformations as a bridge between parametric and nonparametric statistics. Am Statistician 35(3):124–129Google Scholar
  34. 34.
    Wyczalkowska-Tomasik A, Czarkowska-Paczek B, Zielenkiewicz M, Paczek L (2016) Inflammatory Markers Change with Age, but do not Fall Beyond Reported Normal Ranges. Arch Immunol Ther Exp (Warsz) 64(3):249–254CrossRefGoogle Scholar
  35. 35.
    Hayden MS, Ghosh S (2008) Shared principles in NF-kappaB signaling. Cell 132(3):344–362.  https://doi.org/10.1016/j.cell.2008.01.020 PubMedCrossRefGoogle Scholar
  36. 36.
    Stolp HB, Liddelow SA, Sá-Pereira I, Dziegielewska KM, Saunders NR (2013) Immune responses at brain barriers and implications for brain development and neurological function in later life. Front Integr Neurosci 7:61.  https://doi.org/10.3389/fnint.2013.00061 PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    Altinoz MA, Ince B, Tek C, Srihari VH, Guloksuz S (2018) The NF-κB signaling pathway: an important therapeutic target in psychiatric disorders. Mol Psychiatry 23(3):490–491PubMedCrossRefGoogle Scholar
  38. 38.
    Kaltschmidt B, Kaltschmidt C (2015) NF-KappaB in long-term memory and structural plasticity in the adult mammalian brain. Front Mol Neurosci 8:69.  https://doi.org/10.3389/fnmol.2015.00069 PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Wolff V, Schlagowski AI, Rouyer O, Charles AL, Singh F, Auger C, Schini-Kerth V, Marescaux C, Raul JS, Zoll J, Geny B (2015) Tetrahydrocannabinol induces brain mitochondrial respiratory chain dysfunction and increases oxidative stress: a potential mechanism involved in cannabis-related stroke. Biomed Res Int 2015:323706PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    Shiels MS, Katki HA, Freedman ND, Purdue MP, Wentzensen N, Trabert B, Kitahara CM, Furr M, Li Y, Kemp TJ, Goedert JJ, Chang CM, Engels EA, Caporaso NE, Pinto LA, Hildesheim A, Chaturvedi AK (2014) Cigarette smoking and variations in systemic immune and inflammation markers. J Natl Cancer Inst 106(11)Google Scholar
  41. 41.
    Dickerson F, Stallings C, Origoni A, Schroeder J, Katsafanas E, Schweinfurth L, Savage C, Khushalani S, Yolken R (2016) Inflammatory markers in recent onset psychosis and chronic schizophrenia. Schizophr Bull 42(1):134–141.  https://doi.org/10.1093/schbul/sbv108 PubMedCrossRefGoogle Scholar
  42. 42.
    Barron H, Hafizi S, Andreazza AC, Mizrahi R (2017) Neuroinflammation and oxidative stress in psychosis and psychosis risk. Int J Mol Sci 18(3):651.  https://doi.org/10.3390/ijms18030651 PubMedCentralCrossRefGoogle Scholar
  43. 43.
    Leza JC, García-Bueno B, Bioque M, Arango C, Parellada M, Do K, O'Donnell P, Bernardo M (2015) Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev 55:612–626PubMedCrossRefGoogle Scholar
  44. 44.
    Perkins DO, Jeffries CD, Addington J, Bearden CE, Cadenhead KS, Cannon TD, Cornblatt BA et al (2014) Towards a psychosis risk blood diagnostic for persons experiencing high-risk symptoms: preliminary results from the NAPLS project. Schizophr Bull 41(2):419–428.  https://doi.org/10.1093/schbul/sbu099 PubMedPubMedCentralCrossRefGoogle Scholar
  45. 45.
    Metcalf SA, Jones PB, Nordstrom T, Timonen M, Mäki P, Miettunen J, Jääskeläinen E, Järvelin MR, Stochl J, Murray GK, Veijola J, Khandaker GM (2017) Serum C-reactive protein in adolescence and risk of schizophrenia in adulthood: a prospective birth cohort study. Brain Behav Immun 59:253–259PubMedPubMedCentralCrossRefGoogle Scholar
  46. 46.
    Parellada M, Gomez-Vallejo S, Burdeus M, Arango C (2017) Developmental differences between schizophrenia and bipolar disorder. Schizophr Bull 43(6):1176–1189.  https://doi.org/10.1093/schbul/sbx126 PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Martínez-Cengotitabengoa M, Micó JA, Arango C, Castro-Fornieles J, Graell M, Payá B, Leza JC, Zorrilla I, Parellada M, López MP, Baeza I, Moreno C, Rapado-Castro M, González-Pinto A (2014) Basal low antioxidant capacity correlates with cognitive deficits in early onset psychosis A 2-year follow-up study. Schizophr Res 156(1):23–29PubMedCrossRefGoogle Scholar
  48. 48.
    Fraguas D, Gonzalez-Pinto A, Micó JA, Reig S, Parellada M, Martínez-Cengotitabengoa M, Castro-Fornieles J, Rapado-Castro M, Baeza I, Janssen J, Desco M, Leza JC, Arango C (2012) Decreased glutathione levels predict loss of brain volume in children and adolescents with first-episode psychosis in a two-year longitudinal study. Schizophr Res 137(1–3):58–65PubMedCrossRefGoogle Scholar
  49. 49.
    Arango C, Giráldez M, Merchán-Naranjo J, Baeza I, Castro-Fornieles J, Alda JA, Martínez-Cantarero C, Moreno C, de Andrés P, Cuerda C, de la Serna E, Correll CU, Fraguas D, Parellada M (2014) Second-generation antipsychotic use in children and adolescents: a six-month prospective cohort study in drug-naïve patients. J Am Acad Child Adolesc Psychiatry 53(11):1179–1190.  https://doi.org/10.1016/j.jaac.2014.08.009 PubMedCrossRefGoogle Scholar
  50. 50.
    Ridker PM (2007) C-Reactive protein and the prediction of cardiovascular events among those at intermediate risk. Moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol 49 (21):2129–38, https://doi.org/10.1016/j.jacc.2007.02.052 PubMedCrossRefGoogle Scholar
  51. 51.
    Nature Immunology Editorial (2017) A current view on inflammation Evolving mechanistic and conceptual understanding of inflammation drives insight into human disease and new approaches for therapy. Nat Immunol 18:825.  https://doi.org/10.1038/ni.3798 CrossRefGoogle Scholar
  52. 52.
    Arango C, Rapado-Castro M, Reig S, Castro-Fornieles J, González-Pinto A, Otero S, Baeza I, Moreno C, Graell M, Janssen J, Parellada M, Moreno D, Bargalló N, Desco M (2012) Progressive brain changes in children and adolescents with first-episode psychosis. Arch Gen Psychiatry 69(1):16–26PubMedCrossRefGoogle Scholar
  53. 53.
    Juncal-Ruiz M, Riesco-Dávila L, Ortiz-García de la Foz V, Ramírez-Bonilla M, Martínez-García O, Irure-Ventura J, Leza JC, López-Hoyos M, Crespo-Facorro B (2018) The effect of excess weight on circulating inflammatory cytokines in drug-naïve first-episode psychosis individuals. J Neuroinflammation 15:63.  https://doi.org/10.1186/s12974-018-1096-6 PubMedPubMedCentralCrossRefGoogle Scholar
  54. 54.
    Barcones MF, MacDowell KS, García-Bueno B, Bioque M, Gutiérrez-Galve L, González-Pinto A, Parellada M, Bobes J, Bernardo M, Lobo A, Leza JC (2018) Cardiovascular risk in early psychosis: relationship with inflammation and clinical features 6 months after diagnosis. Int J Neuropsychopharmacol 21(5):410–422.  https://doi.org/10.1093/ijnp/pyx110 PubMedCrossRefGoogle Scholar
  55. 55.
    Martínez-Gras I, Pérez-Nievas BG, García-Bueno B, Madrigal JL, Andrés-Estebane E, Rodríguez-Jiménez R, Hoenicka J, Palomo T, Rubio G, Leza JC (2011) The anti-inflammatory prostaglandin 15d-PGJ2 and its nuclear receptor PPARgamma are decreased in schizophrenia. Schizophr Res 128(1–3):15–22.  https://doi.org/10.1016/j.schres.2011.01.018 PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • C. Moreno
    • 1
    Email author
  • M. Parellada
    • 1
  • K. S. MacDowell
    • 2
  • B. García-Bueno
    • 2
  • B. Cabrera
    • 3
  • A. González-Pinto
    • 4
  • P. Saiz
    • 5
  • A. Lobo
    • 6
  • R. Rodriguez-Jimenez
    • 7
    • 8
  • E. Berrocoso
    • 9
  • M. Bernardo
    • 3
    • 10
  • J. C. Leza
    • 2
  • From the FLAMM-PEPs study, Centro de Investigación Biomédica en Red de Salud Mental (CIBERSAM)
  1. 1.Child and Adolescent Psychiatry Department, Hospital General Universitario Gregorio Marañón, School of MedicineUniversidad Complutense (UCM), IiSGMMadridSpain
  2. 2.Department of Pharmacology and Toxicology, Faculty of MedicineUCM, Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), IUINQMadridSpain
  3. 3.Barcelona Clinic Schizophrenia Unit, Neuroscience InstituteHospital Clinic of BarcelonaBarcelonaSpain
  4. 4.Hospital Universitario, Alava, EHU/UPV, BIOARABAVitoriaSpain
  5. 5.Department of Psychiatry, Faculty of MedicineUniversity of OviedoOviedoSpain
  6. 6.Department of Psychiatry, Instituto de Investigación Sanitaria AragónUniversity of ZaragozaZaragozaSpain
  7. 7.Department of PsychiatryInstituto de Investigación HospitalMadridSpain
  8. 8.CogPsy-GroupUniversidad Complutense de Madrid (UCM)MadridSpain
  9. 9.Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, Instituto de Investigación e Innovación en Ciencias Biomédicas de CádizINiBICA, University of CádizCádizSpain
  10. 10.Institut D’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)University of BarcelonaBarcelonaSpain

Personalised recommendations